Project Grant R03AG095807
- The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
- The National Institute on Aging (NIA) awarded a $805,295 Project Grant under the Aging Research federal grant program (CFDA 93.866) to The Leland Stanford Junior University, effective April 1, 2025 through March 31, 2030. The purpose of this grant is to examine cerebrospinal fluid (CSF) and blood biomarkers to gain insights into the pathways leading to postoperative delirium and neurocognitive dysfunction, which commonly occur after surgical procedures and are associated with declines in...
- This $2,356,117 federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to improve the perioperative management of patients with Alzheimer's disease and related dementias. The primary objectives are to: (1) identify the extent to which surgical patients with these conditions are at increased risk for adverse postoperative outcomes, and (2) estimate the association between various perioperative interventions and the incidence...
- This Project Grant award of $619,681 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to develop innovative tools and techniques for studying the complex genetic interactions underlying the development of Alzheimer's disease (AD). The award, with a period of performance from March 2025 to January 2030, will enable the Leland Stanford Junior University to create "Combo-Seq/Tag", a toolkit that combines gene editing to install multiple AD risk...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- This $165,888 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to The Leland Stanford Junior University aims to develop novel neuroimaging and genomic markers to characterize the glymphatic system in Alzheimer's disease. The researchers will employ a combination of advanced MRI techniques, including intravoxel incoherent motion (IVIM), 3D amplified MRI, and perivascular space volume imaging, to gain a comprehensive understanding of the brain's waste...
- This $1,526,066 Project Grant was awarded by the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), to The Leland Stanford Junior University (Stanford University). The award, with a start date of June 1, 2025 and an ultimate completion date of April 30, 2030, will fund research to investigate the shared mechanisms of tau protein toxicity across multiple neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's disease. The...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $167,940 project grant to The Children's Hospital Corporation (Boston Children's Hospital) to elucidate the neuronal mechanisms underlying cognitive resilience to Alzheimer's disease. The project, awarded on August 15, 2025, aims to (1) determine if the MEF2 transcription factors mediate survival of specific neuronal subtypes vulnerable to Alzheimer's pathology, (2) assess whether...
- The National Institute on Aging (NIA) awarded a $1,459,072 project grant to the J. David Gladstone Institutes under the Aging Research Federal Grant Program (CFDA 93.866) to monitor and manipulate inhibitory interneuron cell populations in mouse models of Alzheimer's disease. The 2-year project aims to use dual cell-type-specific enhancer-associated adeno-associated viruses (enhancer-AAVs) to independently monitor and control parvalbumin (PVALB) and somatostatin (SST) inhibitory interneurons...
- This Project Grant award of $762,636 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research by The Leland Stanford Junior University to develop interpretable machine learning (ML) methods for analyzing the genetics of Alzheimer's disease (AD). The objective is to discover causal genetic variants that could lead to new AD therapies. The work involves pairing rigorous feature selection in ML with causal inference to identify genetic variants that influence AD risk,...
This $385,000 Project Grant awarded by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) will support research at Stanford University to determine how the enzyme aldehyde dehydrogenase 2 (ALDH2) regulates oxidative stress during anesthesia, with a focus on the role of ALDH2 in the context of Alzheimer's disease. The research aims to elucidate the mechanism by which aging-related oxidative stress contributes to prolonged neurological recovery after anesthesia, particularly in models with impaired ALDH2 activity and Alzheimer's pathology. By leveraging mouse models and a small-molecule ALDH2 activator, the project will seek to determine if increasing ALDH2 activity can improve anesthetic neurocognitive recovery in aged mice. The award period runs from August 15, 2025 through July 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $385.0k | 8/6/25 |